SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Peter Eaton, Clícia R. Bittencourt, Vladimir Costa Silva, Leiz M.C. Véras, Carlos H.N. Costa, Maria J. Feio, José Roberto S.A. Leite, Anti-leishmanial activity of the antimicrobial peptide DRS 01 observed in Leishmania infantum (syn. Leishmania chagasi) cells, Nanomedicine: Nanotechnology, Biology and Medicine, 2014, 10, 2, 483

    CrossRef

  2. 2
    Arpita Kulshrestha, Vanila Sharma, Ruchi Singh, Poonam Salotra, Comparative transcript expression analysis of miltefosine-sensitive and miltefosine-resistant Leishmania donovani, Parasitology Research, 2014, 113, 3, 1171

    CrossRef

  3. 3
    Shyam Sundar, Anup Singh, Om Prakash Singh, Strategies to Overcome Antileishmanial Drugs Unresponsiveness, Journal of Tropical Medicine, 2014, 2014, 1

    CrossRef

  4. 4
    Sushmita Das, Mukta Rani, Vidyanand Rabidas, Krishna Pandey, Ganesh Chandra Sahoo, Pradeep Das, TLR9 and MyD88 are crucial for the maturation and activation of dendritic cells by paromomycin–miltefosine combination therapy in visceral leishmaniasis, British Journal of Pharmacology, 2014, 171, 5
  5. 5
    Marleen Boelaert, Shyam Sundar, Manson's Tropical Infectious Diseases, 2014,

    CrossRef

  6. You have free access to this content6
    Surendra Uranw, Bart Ostyn, Thomas P.C. Dorlo, Epco Hasker, Bruno Dujardin, Jean-Claude Dujardin, Suman Rijal, Marleen Boelaert, Adherence to miltefosine treatment for visceral leishmaniasis under routine conditions in Nepal, Tropical Medicine & International Health, 2013, 18, 2
  7. 7
    S. Das, K. Pandey, V. N. Rabidas, A. Mandal, P. Das, Effectiveness of miltefosine treatment in targeting anti-leishmanial HO-1/Nrf-2-mediated oxidative responses in visceral leishmaniasis patients, Journal of Antimicrobial Chemotherapy, 2013, 68, 9, 2059

    CrossRef

  8. 8
    Shahram Khademvatan, Neda Adibpour, Alborz Eskandari, Saeed Rezaee, Mahmoud Hashemitabar, Fakher Rahim, In silico and in vitro comparative activity of novel experimental derivatives against Leishmania major and Leishmania infantum promastigotes, Experimental Parasitology, 2013, 135, 2, 208

    CrossRef

  9. 9
    S. Rijal, B. Ostyn, S. Uranw, K. Rai, N. R. Bhattarai, T. P. C. Dorlo, J. H. Beijnen, M. Vanaerschot, S. Decuypere, S. S. Dhakal, M. L. Das, P. Karki, R. Singh, M. Boelaert, J.-C. Dujardin, Increasing Failure of Miltefosine in the Treatment of Kala-azar in Nepal and the Potential Role of Parasite Drug Resistance, Reinfection, or Noncompliance, Clinical Infectious Diseases, 2013, 56, 11, 1530

    CrossRef

  10. 10
    T.T.H. Pham, G. Barratt, J.P. Michel, P.M. Loiseau, M. Saint-Pierre-Chazalet, Interactions of antileishmanial drugs with monolayers of lipids used in the development of amphotericin B–miltefosine-loaded nanocochleates, Colloids and Surfaces B: Biointerfaces, 2013, 106, 224

    CrossRef

  11. 11
    T.T.H. Pham, P.M. Loiseau, G. Barratt, Strategies for the design of orally bioavailable antileishmanial treatments, International Journal of Pharmaceutics, 2013, 454, 1, 539

    CrossRef

  12. 12
    Santosh Kumar, Avinash Tiwari, S.N. Suryawanshi, Monika Mittal, Preeti Vishwakarma, Suman Gupta, Chemotherapy of leishmaniasis. Part IX: Synthesis and bioevaluation of aryl substituted ketene dithioacetals as antileishmanial agents, Bioorganic & Medicinal Chemistry Letters, 2012, 22, 21, 6728

    CrossRef

  13. 13
    A. Fortin, S. Hendrickx, V. Yardley, P. Cos, H. Jansen, L. Maes, Efficacy and tolerability of oleylphosphocholine (OlPC) in a laboratory model of visceral leishmaniasis, Journal of Antimicrobial Chemotherapy, 2012, 67, 11, 2707

    CrossRef

  14. 14
    K. Aït-Oudhia, E. Gazanion, D. Sereno, B. Oury, J.P. Dedet, F. Pratlong, L. Lachaud, In vitro susceptibility to antimonials and amphotericin B of Leishmania infantum strains isolated from dogs in a region lacking drug selection pressure, Veterinary Parasitology, 2012, 187, 3-4, 386

    CrossRef

  15. 15
    Asok Kumar Mukherjee, Gaurav Gupta, Anupam Adhikari, Saikat Majumder, Santanu Kar Mahapatra, Suchandra Bhattacharyya Majumdar, Subrata Majumdar, Miltefosine triggers a strong proinflammatory cytokine response during visceral leishmaniasis: Role of TLR4 and TLR9, International Immunopharmacology, 2012, 12, 4, 565

    CrossRef

  16. 16
    L. C. Rubiano, M. C. Miranda, S. Muvdi Arenas, L. M. Montero, I. Rodriguez-Barraquer, D. Garcerant, M. Prager, L. Osorio, M. X. Rojas, M. Perez, R. S. Nicholls, N. Gore Saravia, Noninferiority of Miltefosine Versus Meglumine Antimoniate for Cutaneous Leishmaniasis in Children, Journal of Infectious Diseases, 2012, 205, 4, 684

    CrossRef

  17. 17
    Aditya Verma, Saumya Srivastava, Shraddha A. Sane, Vijay K. Marrapu, Nagarapu Srinivas, Manisha Yadav, Kalpana Bhandari, Suman Gupta, Antileishmanial activity of benzocycloalkyl azole oximino ethers: The conformationally constraint analogues of oxiconazole, Acta Tropica, 2011, 117, 2, 157

    CrossRef

  18. 18
    Johan van Griensven, Marleen Boelaert, Combination therapy for visceral leishmaniasis, The Lancet, 2011, 377, 9764, 443

    CrossRef

  19. 19
    Shraddha A. Sane, Nishi Shakya, Suman Gupta, Immunomodulatory effect of picroliv on the efficacy of paromomycin and miltefosine in combination in experimental visceral leishmaniasis, Experimental Parasitology, 2011, 127, 2, 376

    CrossRef

  20. 20
    Elodie Gazanion, Baptiste Vergnes, Marie Seveno, Deborah Garcia, Bruno Oury, Khatima Ait-Oudhia, Ali Ouaissi, Denis Sereno, In vitro activity of nicotinamide/antileishmanial drug combinations, Parasitology International, 2011, 60, 1, 19

    CrossRef

  21. 21
    José Julián Pérez-Cordero, José Manuel Lozano, Jimena Cortés, Gabriela Delgado, Leishmanicidal activity of synthetic antimicrobial peptides in an infection model with human dendritic cells, Peptides, 2011, 32, 4, 683

    CrossRef

  22. 22
    Suvadip Mallick, Aritri Dutta, Joydip Ghosh, Sourav Maiti, Ajay Kumar Mandal, Rajat Banerjee, Chandrakanta Bandyopadhyay, Chiranjib Pal, Protective Therapy with Novel Chromone Derivative against <i>Leishmania donovani</i> Infection Induces Th1 Response in vivo, Chemotherapy, 2011, 57, 5, 388

    CrossRef

  23. 23
    Pierre A. Buffet, Éric Rosenthal, Jean-Pierre Gangneux, Edward Lightburne, Pierre Couppié, Gloria Morizot, Laurence Lachaud, Pierre Marty, Jean-Pierre Dedet, Traitement des leishmanioses en France : proposition d’un référentiel consensuel, La Presse Médicale, 2011, 40, 2, 173

    CrossRef

  24. 24
    Arun Kumar Haldar, Pradip Sen, Syamal Roy, Use of Antimony in the Treatment of Leishmaniasis: Current Status and Future Directions, Molecular Biology International, 2011, 2011, 1

    CrossRef

  25. 25
    Johan van Griensven, Manica Balasegaram, Filip Meheus, Jorge Alvar, Lutgarde Lynen, Marleen Boelaert, Combination therapy for visceral leishmaniasis, The Lancet Infectious Diseases, 2010, 10, 3, 184

    CrossRef

  26. 26
    S. A. Sane, N. Shakya, W. Haq, S. Gupta, CpG oligodeoxynucleotide augments the antileishmanial activity of miltefosine against experimental visceral leishmaniasis, Journal of Antimicrobial Chemotherapy, 2010, 65, 7, 1448

    CrossRef

  27. 27
    C. Mary, F. Faraut, M. Deniau, J. Dereure, K. Aoun, S. Ranque, R. Piarroux, Frequency of Drug Resistance Gene Amplification in ClinicalLeishmaniaStrains, International Journal of Microbiology, 2010, 2010, 1

    CrossRef

  28. 28
    Shyam Sundar, Rakesh Arora, S. P. Singh, Marleen Boelaert, Beena Varghese, Household cost-of-illness of visceral leishmaniasis in Bihar, India, Tropical Medicine & International Health, 2010, 15,
  29. 29
    B.H. Thiers, Efficacy of a weekly cryotherapy regimen to treat Leishmania major cutaneous leishmaniasis, Yearbook of Dermatology and Dermatologic Surgery, 2009, 2009, 204

    CrossRef

  30. 30
    Sassan Noazin, Ali Khamesipour, Lawrence H. Moulton, Marcel Tanner, Kiumarss Nasseri, Farrokh Modabber, Iraj Sharifi, E.A.G. Khalil, Ivan Dario Velez Bernal, Carlos M.F. Antunes, Peter G. Smith, Efficacy of killed whole-parasite vaccines in the prevention of leishmaniasis—A meta-analysis, Vaccine, 2009, 27, 35, 4747

    CrossRef

  31. You have free access to this content31
    T. A. Patel, D. N. Lockwood, Pentamidine as secondary prophylaxis for visceral leishmaniasis in the immunocompromised host: report of four cases, La pentamidine comme prophylaxie secondaire de la leishmaniose viscérale chez l’hôte immunodéprimé: rapport de quatre cas, La Pentamidina como profilaxis secundaria para la leishmaniasis visceral en hospederos inmunocomprometidos: reporte de cuatro casos, Tropical Medicine & International Health, 2009, 14, 9
  32. 32
    Yolanda Mueller, Dawson B. Mbulamberi, Peter Odermatt, Axel Hoffmann, Louis Loutan, François Chappuis, Risk factors for in-hospital mortality of visceral leishmaniasis patients in eastern Uganda, Tropical Medicine & International Health, 2009, 14, 8
  33. 33
    Ibrahim M. Mosleh, Eid Geith, Lina Natsheh, Gabrielle Schönian, Nabil Abotteen, Sa'ad Kharabsheh, Efficacy of a weekly cryotherapy regimen to treat Leishmania major cutaneous leishmaniasis, Journal of the American Academy of Dermatology, 2008, 58, 4, 617

    CrossRef

  34. 34
    Sassan Noazin, Farrokh Modabber, Ali Khamesipour, Peter G. Smith, Lawrence H. Moulton, Kiumarss Nasseri, Iraj Sharifi, Eltahir A.G. Khalil, Ivan Dario Velez Bernal, Carlos M.F. Antunes, Marie Paule Kieny, Marcel Tanner, First generation leishmaniasis vaccines: A review of field efficacy trials, Vaccine, 2008, 26, 52, 6759

    CrossRef

  35. 35
    M. Gabriela Cabrera-Serra, Basilio Valladares, Jose E. Piñero, In vivo activity of perifosine against Leishmania amazonensis, Acta Tropica, 2008, 108, 1, 20

    CrossRef

  36. 36
    Y. Mueller, A. Nguimfack, P. Cavailler, S. Couffignal, J. B. Rwakimari, L. Loutan, F. Chappuis, Safety and effectiveness of amphotericin B deoxycholate for the treatment of visceral leishmaniasis in Uganda, Annals of Tropical Medicine & Parasitology, 2008, 102, 1, 11

    CrossRef

  37. 37
    Mahreen Ameen, Cutaneous leishmaniasis: therapeutic strategies and future directions, Expert Opinion on Pharmacotherapy, 2007, 8, 16, 2689

    CrossRef

  38. 38
    V. Vanlerberghe, G. Diap, P. J. Guerin, F. Meheus, S. Gerstl, P. Van der Stuyft, M. Boelaert, Drug policy for visceral leishmaniasis: a cost-effectiveness analysis, Politique des médicaments contre la leishmaniose viscérale: une analyse de coût efficacité, Política de medicamentos para la Leishmaniasis Visceral: análisis de costo-efectividad, Tropical Medicine & International Health, 2007, 12, 2
  39. 39
    Rilza B. Gayoso Azeredo-Coutinho, Sergio C. F. Mendonça, Heather Callahan, Andréia C. Portal, Max Grögl, SENSITIVITY OF LEISHMANIA BRAZILIENSIS PROMASTIGOTES TO MEGLUMINE ANTIMONIATE (GLUCANTIME) IS HIGHER THAN THAT OF OTHER LEISHMANIA SPECIES AND CORRELATES WITH RESPONSE TO THERAPY IN AMERICAN TEGUMENTARY LEISHMANIASIS, Journal of Parasitology, 2007, 93, 3, 688

    CrossRef

  40. 40
    François Chappuis, Shyam Sundar, Asrat Hailu, Hashim Ghalib, Suman Rijal, Rosanna W. Peeling, Jorge Alvar, Marleen Boelaert, Visceral leishmaniasis: what are the needs for diagnosis, treatment and control?, Nature Reviews Microbiology, 2007, 5, 11, S7

    CrossRef

  41. 41
    Koert Ritmeijer, Abren Dejenie, Yibeltal Assefa, Tadesse Beyene Hundie, Jo Mesure, Gerry Boots, Margriet den Boer, Robert N. Davidson, A Comparison of Miltefosine and Sodium Stibogluconate for Treatment of Visceral Leishmaniasis in an Ethiopian Population with High Prevalence of HIV Infection, Clinical Infectious Diseases, 2006, 43, 3, 357

    CrossRef

  42. 42
    S. Gerstl, R. Amsalu, K. Ritmeijer, Accessibility of diagnostic and treatment centres for visceral leishmaniasis in Gedaref State, northern Sudan, Accessibilité au diagnostic et au traitement de la leishmaniose viscérale dans l’état de Gedaref au nord du Soudan, Accesibilidad a centros de diagnóstico y tratamiento de leishmaniasis visceral en el estado de Gedaref, norte de Sudan, Tropical Medicine & International Health, 2006, 11, 2
  43. 43
    Filip Meheus, Marleen Boelaert, Rob Baltussen, Shyam Sundar, Costs of patient management of visceral leishmaniasis in Muzaffarpur, Bihar, India, Coûts de la prise en charge de patients à la leishmaniose viscérale à Muzaffarpur en Inde, Costes del manejo del paciente con Leishmaniasis Visceral en Muzaffarpur, India, Tropical Medicine & International Health, 2006, 11, 11
  44. 44
    Utpal Kant Singh, Rajniti Prasad, O. P. Mishra, B. P. Jayswal, Miltefosine in children with visceral leishmaniasis: A prospective, multicentric, cross-sectional study, The Indian Journal of Pediatrics, 2006, 73, 12, 1077

    CrossRef

  45. 45
    J. Berman, A.D.M. Bryceson, S. Croft, J. Engel, W. Gutteridge, J. Karbwang, H. Sindermann, J. Soto, S. Sundar, J.A. Urbina, Miltefosine: issues to be addressed in the future, Transactions of the Royal Society of Tropical Medicine and Hygiene, 2006, 100, S41

    CrossRef

  46. 46
    Caryn Bern, Jill Adler-Moore, Juan Berenguer, Marleen Boelaert, Margriet den Boer, Robert N. Davidson, Concepcion Figueras, Luigi Gradoni, Dimitris A. Kafetzis, Koert Ritmeijer, Eric Rosenthal, Catherine Royce, Rosario Russo, Shyam Sundar, Jorge Alvar, Reviews Of Anti-infective Agents: Liposomal Amphotericin B for the Treatment of Visceral Leishmaniasis, Clinical Infectious Diseases, 2006, 43, 7, 917

    CrossRef

  47. 47
    Margriet den Boer, Robert N Davidson, Treatment options for visceral leishmaniasis, Expert Review of Anti-infective Therapy, 2006, 4, 2, 187

    CrossRef

  48. 48
    Jorge Alvar, Simon Croft, Piero Olliaro, Control of Human Parasitic Diseases, 2006,

    CrossRef

  49. 49
    Suman Gupta, Ramesh, S.C. Sharma, V.M.L. Srivastava, Efficacy of picroliv in combination with miltefosine, an orally effective antileishmanial drug against experimental visceral leishmaniasis, Acta Tropica, 2005, 94, 1, 41

    CrossRef

  50. 50
    R. Reithinger, M. Mohsen, M. Wahid, M. Bismullah, R. J. Quinnell, C. R. Davies, J. Kolaczinski, J. R. David, Efficacy of Thermotherapy to Treat Cutaneous Leishmaniasis Caused byLeishmania tropicain Kabul, Afghanistan: A Randomized, Controlled Trial, Clinical Infectious Diseases, 2005, 40, 8, 1148

    CrossRef

  51. 51
    P. Desjeux, Options thérapeutiques pour la leishmaniose viscérale, Médecine et Maladies Infectieuses, 2005, 35, S74

    CrossRef

  52. 52
    Piero L Olliaro, Philippe J Guerin, Sibylle Gerstl, Astrid Aga Haaskjold, John-Arne Rottingen, Shyam Sundar, Treatment options for visceral leishmaniasis: a systematic review of clinical studies done in India, 1980–2004, The Lancet Infectious Diseases, 2005, 5, 12, 763

    CrossRef

  53. 53
    M. A. Dea-Ayuela, S. Rama-Íñiguez, J. A. Sánchez-Brunete, J. J. Torrado, J. M. Alunda, F. Bolás-Fernández, Anti-leishmanial activity of a new formulation of amphotericin B, Tropical Medicine & International Health, 2004, 9, 9
  54. 54
    Sujit K. Bhattacharya, T. K. Jha, Shyam Sundar, C. P. Thakur, Juergen Engel, Herbert Sindermann, Klaus Junge, Juntra Karbwang, Anthony D. M. Bryceson, Jonathan D. Berman, Efficacy and Tolerability of Miltefosine for Childhood Visceral Leishmaniasis in India, Clinical Infectious Diseases, 2004, 38, 2, 217

    CrossRef

  55. 55
    H. Sindermann, K. R. Engel, C. Fischer, W. Bommer, Oral Miltefosine for Leishmaniasis in Immunocompromised Patients: Compassionate Use in 39 Patients with HIV Infection, Clinical Infectious Diseases, 2004, 39, 10, 1520

    CrossRef

  56. 56
    Pierre Bau, Jacques Bolard, Jean Dupouy-Camet, Heated amphotericin to treat leishmaniasis, The Lancet Infectious Diseases, 2003, 3, 4, 188

    CrossRef

  57. 57
    S. Rijal, F. Chappuis, R. Singh, P.A. Bovier, P. Acharya, B.M.S. Karki, M.L. Das, P. Desjeux, L. Loutan, S. Koirala, Treatment of visceral leishmaniasis in south-eastern Nepal: decreasing efficacy of sodium stibogluconate and need for a policy to limit further decline, Transactions of the Royal Society of Tropical Medicine and Hygiene, 2003, 97, 3, 350

    CrossRef

  58. 58
    Shyam Sundar, Madhukar Rai, Advances in the treatment of leishmaniasis, Current Opinion in Infectious Diseases, 2002, 15, 6, 593

    CrossRef

  59. 59
    Shyam Sundar, T.K. Jha, C.P. Thakur, Juergen Engel, Herbert Sindermann, Christina Fischer, Klaus Junge, Anthony Bryceson, Jonathan Berman, Oral Miltefosine for Indian Visceral Leishmaniasis, New England Journal of Medicine, 2002, 347, 22, 1739

    CrossRef

  60. 60
    Eric Rosenthal, Pierre Marty, Treatment of visceral leishmaniasis: a review of current treatment practices, Expert Opinion on Pharmacotherapy, 2002, 3, 8, 1101

    CrossRef

  61. 61
    Philippe J Guerin, Piero Olliaro, Shyam Sundar, Marleen Boelaert, Simon L Croft, Philippe Desjeux, Monique K Wasunna, Anthony DM Bryceson, Visceral leishmaniasis: current status of control, diagnosis, and treatment, and a proposed research and development agenda, The Lancet Infectious Diseases, 2002, 2, 8, 494

    CrossRef

  62. 62
    Jorge Alvar, Urbà González, Mariona Pinart, Soumik Kalita, Mercè Herrero, Ivan D Vélez, Shyam Sundar, Interventions for visceral leishmaniasis, The Cochrane Library,
  63. 63
    Poonam Salotra, Ruchi Singh, Karin Seifert, Visceral Leishmaniasis – Current Treatments and Needs,